Onkologie. 2024:18(5):325-329 | DOI: 10.36290/xon.2024.068

Early ocular toxicity of targeted therapy in metastatic melanoma

Miroslav Důra¹, Johana Glezgová², Ivana Krajsová¹

¹ Dermatovenerologická klinika, 1. LF UK a VFN, Praha

² Oční klinika, 1. LF UK a VFN, Praha

The authors describe a clinical case of a patient with metastatic melanoma treated with the targeted therapy by encorafenib and binimetinib. In the very beginning of the treatment, the ocular toxicity in the form of the bilateral detachment of the outer retinal layers was detected. Subjective symptoms disappeared in 2 months and follow-up OCT confirmed the restoration of the detachment. The targeted therapy with dabrafenib and trametinib in the subsequent line of the treatment was not complicated by the symptoms of the ocular toxicity. The article discusses the ocular toxicity of the targeted therapy in melanoma, its types, grading, and management. During each patient's visit in case the patient is treated with the targeted therapy by BRAF and MEK inhibitor, the patient should be asked about any subjective vision impairment. The close cooperation with the ophthalmology specialist is crucial for the early and correct diagnosis of the ocular toxicity.

Keywords: targeted therapy, encorafenib, binimetinib, melanoma, ocular toxicity, retinopathy.

Accepted: November 18, 2024; Published: November 28, 2024  Show citation